Akero Therapeutics, Inc.Akero Therapeutics, Inc.Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪3.77 B‬EUR
−3.23EUR
‪−243.48 M‬EUR
0.00EUR
‪71.26 M‬
Beta (1Y)
0.40
Employees (FY)
63
Change (1Y)
+7 +12.50%
Revenue / Employee (1Y)
0.00EUR
Net income / Employee (1Y)
‪−3.86 M‬EUR

About Akero Therapeutics, Inc.


CEO
Andrew Cheng
Headquarters
South San Francisco
Founded
2017
ISIN
US00973Y1082
FIGI
BBG01TNW8PW0
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Check out other big names from the same industry as 1AKRO.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
XBI
State Street SPDR S&P Biotech ETF
Weight
1.51%
Market value
‪96.24 M‬
USD
IWM
iShares Russell 2000 ETF
Weight
0.13%
Market value
‪91.29 M‬
USD
VXF
Vanguard Extended Market ETF
Weight
0.04%
Market value
‪37.45 M‬
USD
IWO
iShares Russell 2000 Growth ETF
Weight
0.25%
Market value
‪32.85 M‬
USD
IBB
iShares Biotechnology ETF
Weight
0.35%
Market value
‪23.68 M‬
USD
SCHA
Schwab U.S. Small-Cap ETF
Weight
0.10%
Market value
‪19.09 M‬
USD
VTWO
Vanguard Russell 2000 ETF
Weight
0.11%
Market value
‪15.81 M‬
USD
VHT
Vanguard Health Care ETF
Weight
0.04%
Market value
‪7.89 M‬
USD
SURI
Simplify Propel Opportunities ETF
Weight
11.17%
Market value
‪7.85 M‬
USD
LABU
Direxion Daily S&P Biotech Bull 3X Shares
Weight
1.90%
Market value
‪7.74 M‬
USD
DFAS
Dimensional U.S. Small Cap ETF
Weight
0.07%
Market value
‪7.67 M‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of 1AKRO is 46.35 EUR — it has decreased by −1.13% in the past 24 hours. Watch Akero Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange Akero Therapeutics, Inc. stocks are traded under the ticker 1AKRO.
1AKRO stock has fallen by −1.26% compared to the previous week, the month change is a 15.70% rise, over the last year Akero Therapeutics, Inc. has showed a 28.61% increase.
We've gathered analysts' opinions on Akero Therapeutics, Inc. future price: according to them, 1AKRO price has a max estimate of 51.86 EUR and a min estimate of 46.67 EUR. Watch 1AKRO chart and read a more detailed Akero Therapeutics, Inc. stock forecast: see what analysts think of Akero Therapeutics, Inc. and suggest that you do with its stocks.
1AKRO reached its all-time high on Jun 6, 2025 with the price of 48.88 EUR, and its all-time low was 33.80 EUR and was reached on May 19, 2025. View more price dynamics on 1AKRO chart.
See other stocks reaching their highest and lowest prices.
1AKRO stock is 1.14% volatile and has beta coefficient of 0.40. Track Akero Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Akero Therapeutics, Inc. there?
Today Akero Therapeutics, Inc. has the market capitalization of ‪3.77 B‬, it has increased by 0.71% over the last week.
Yes, you can track Akero Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Akero Therapeutics, Inc. is going to release the next earnings report on Nov 12, 2025. Keep track of upcoming events with our Earnings Calendar.
1AKRO earnings for the last quarter are −0.73 EUR per share, whereas the estimation was −0.78 EUR resulting in a 6.23% surprise. The estimated earnings for the next quarter are −0.79 EUR per share. See more details about Akero Therapeutics, Inc. earnings.
Akero Therapeutics, Inc. revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
1AKRO net income for the last quarter is ‪−59.85 M‬ EUR, while the quarter before that showed ‪−65.37 M‬ EUR of net income which accounts for 8.45% change. Track more Akero Therapeutics, Inc. financial stats to get the full picture.
No, 1AKRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2025, the company has 63 employees. See our rating of the largest employees — is Akero Therapeutics, Inc. on this list?
Like other stocks, 1AKRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Akero Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.